The estimated Net Worth of Nancy Wysenski is at least $11.7 millió dollars as of 7 July 2023. Ms. Wysenski owns over 5,957 units of Alkermes plc stock worth over $578,854 and over the last 15 years she sold ALKS stock worth over $10,796,661. In addition, she makes $356,236 as Independent Director at Alkermes plc.
Sign up
Ms. Wysenski ALKS stock SEC Form 4 insiders trading
Nancy has made over 12 trades of the Alkermes plc stock since 2011, according to the Form 4 filled with the SEC. Most recently she exercised 5,957 units of ALKS stock worth $158,277 on 7 July 2023.
The largest trade she's ever made was selling 185,704 units of Alkermes plc stock on 7 May 2012 worth over $10,410,566. On average, Nancy trades about 6,595 units every 62 days since 2009. As of 7 July 2023 she still owns at least 21,786 units of Alkermes plc stock.
You can see the complete history of Ms. Wysenski stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Nancy Wysenski biography
Nancy J. Wysenski is Independent Director of the Company. Ms. Wysenski served as the Executive Vice President and Chief Commercial Officer of Vertex Pharmaceuticals Incorporated (“Vertex”) from December 2009 through June 2012. Prior to joining Vertex, Ms. Wysenski held the position of Chief Operating Officer of Endo Pharmaceuticals plc (“Endo”), a specialty pharmaceutical company, where she led sales, marketing, commercial operations, supply chain management, human resources and various business development initiatives. Prior to her role at Endo, Ms. Wysenski participated in the establishment of EMD Pharmaceuticals, Inc., where she held various leadership positions, including the role of President and Chief Executive Officer from 2001 to 2006 and Vice President of Commercial from 1999 to 2001. From 1984 to 1998, Ms. Wysenski held several sales-focused roles at major pharmaceutical companies, including Vice President of Field Sales for Astra Merck, Inc. Ms. Wysenski formerly served as a director for Reata Pharmaceuticals, Inc., now a publicly-traded biopharmaceutical company, and more recently served as a director for Inovio Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, from March 2015 to May 2017, and Dova Pharmaceuticals Inc., formerly a publicly-traded biopharmaceutical company, from June 2018 to November 2019. She is a founder of the Research Triangle Park chapter of the Healthcare Business Women’s Association and served on the Nominating Committee and National Advisory Board of the Healthcare Businesswomen’s Association.
What is the salary of Nancy Wysenski?
As the Independent Director of Alkermes plc, the total compensation of Nancy Wysenski at Alkermes plc is $356,236. There are 16 executives at Alkermes plc getting paid more, with Richard Pops having the highest compensation of $14,637,100.
How old is Nancy Wysenski?
Nancy Wysenski is 62, she's been the Independent Director of Alkermes plc since 2017. There are 10 older and 12 younger executives at Alkermes plc. The oldest executive at Alkermes plc is Dr. Floyd E. Bloom M.D., 84, who is the Founder.
What's Nancy Wysenski's mailing address?
Nancy's mailing address filed with the SEC is 350, Oyster Point Boulevard, South San Francisco, San Mateo County, California, 94080, United States.
Insiders trading at Alkermes plc
Over the last 13 years, insiders at Alkermes plc have traded over $407,046,771 worth of Alkermes plc stock and bought 86,119 units worth $2,034,840 . The most active insiders traders include Corp Plc Elan Science Three..., Richard F Pops és James M Frates. On average, Alkermes plc executives and independent directors trade stock every 5 days with the average trade being worth of $1,083,232. The most recent stock trade was executed by David Joseph Gaffin on 3 August 2024, trading 2,014 units of ALKS stock currently worth $53,512.
What does Alkermes plc do?
alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.
What does Alkermes plc's logo look like?
Complete history of Ms. Wysenski stock trades at Alkermes plc, Cytokinetics Inc, Inovio Pharmaceuticals Inc, Tetraphase Pharmaceuticals, Vertex Pharmaceuticals és Provention Bio
Alkermes plc executives and stock owners
Alkermes plc executives and other stock owners filed with the SEC include:
-
Richard Pops,
Chairman of the Board, Chief Executive Officer -
Craig Hopkinson,
Executive Vice President, Research and Development and Chief Medical Officer -
David Gaffin,
Senior Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary -
James Frates,
Chief Financial Officer, Senior Vice President -
Michael Landine,
Senior Vice President - Corporate Development, Chief Risk Officer -
Richard F. Pops,
Chairman & CEO -
Dr. Craig C. Hopkinson,
Exec. VP of R&D and Chief Medical Officer -
David Joseph Gaffin,
Sr. VP, Chief Legal Officer, Chief Compliance Officer & Sec. -
Frank Wilson,
Independent Director -
Richard Gaynor,
Independent Director -
Michael J. Landine,
Sr. VP of Corp. Devel. & Chief Risk Officer -
Paul Mitchell,
Independent Director -
Robert Breyer,
Independent Director -
David Anstice,
Lead Independent Director -
Nancy Snyderman,
Independent Director -
Wendy Dixon,
Independent Director -
Nancy Wysenski,
Independent Director -
Shane Cooke,
Director -
Iain Brown,
Senior Vice President - Finance, Chief Accounting Officer -
Peter Norman,
Sr. VP of Policy & Gov. Relations -
Iain Michael Brown,
Sr. VP & CFO -
Dr. Floyd E. Bloom M.D.,
Founder -
Stephen Schiavo,
Sr. VP of HR -
Eva Stroynowski,
VP of Product & R&D Communications, Public Affairs -
Sandra Coombs,
Co-Head of Investor Relations -
Blair C. Jackson,
Exec. VP & COO -
Dr. Floyd E. Bloom,
Founder -
Floyd E Bloom,
Director -
Elliot Ehrich,
SVP, R&D & CMO, Alkermes, Inc. -
Mark Stejbach,
Chief Commercial Officer -
James A. Jr. Robinson,
President & COO,Alkermes, Inc. -
Nancy Lurker,
Director -
Rebecca Peterson,
SVP, Corporate Communications -
Geraldine Henwood,
Director -
Kathryn L Biberstein,
SVP, GC, Secretary, Alks, Inc. -
Gordon G Pugh,
SVP, COO & CRO, Alkermes, Inc. -
James L Botkin,
SVP, Alkermes Gainesville LLC -
Mark B Skaletsky,
Director -
Corp Plc Elan Science Three...,
-
Christian Todd Nichols,
SVP, Chief Commercial Officer -
Brian P Mckeon,
Director -
David Angelo Jr. Daglio,
Director -
Blair Curtis Jackson,
EVP, Chief Operating Officer -
Emily Peterson Alva,
Director -
Cato T Laurencin,
Director -
Christopher I Wright,
Director -
Samuel Joseph Parisi,
VP, Finance (Interim PAO)